Sepracor (SEPR ) shares surged after the company received an "approvable" letter from the FDA for its New Drug Application for Estorra brand eszopiclone. Deutsche Bank reportedly upgraded the shares to buy from hold. Morgan Stanley upped the stock to equal-weight from underweight.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.